Clinical trial
A Phase II, Trial to Assess the Safety and Tolerability of Influenza Virus…
NCT00192179 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT00192179 |
|---|---|
| Title | A Phase II, Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, CAIV-T in Healthy Children and Adolescents Ages 6 to Less Than 18 Years. |
| Official title | A Phase II, Prospective, Randomized, Double-Blind, Placebo, Controlled Trial, to Assess the Safety and Tolerability of Influenza Virus Vaccine, Trivalent, Types A & B Live Cold-Adapted Liquid Formulation (CAIV-T) in Healthy Children and Adolescents Ages 6 to Less Than 18 Years. |
| Acronym | FluMist |
| Lead sponsor | MedImmune LLC, Industry |
| Collaborators | Wyeth is now a wholly owned subsidiary of Pfizer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Influenza |
| Intervention type | Biological |
| Interventions | Cold-adapted influenza vaccine trivalent (CAIV-T), Placebo |
| Enrollment | 240 |
| Start date | Jun 1, 2003 |
| Primary completion | Jul 1, 2003 |
| Completion | Jul 1, 2003 |
| First posted | Sep 19, 2005 |
| Last update posted | Mar 2, 2012 |
| Countries | Belgium, Poland, United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: